MarketScreener Homepage > Equities > Nasdaq > HOOKIPA Pharma Inc. HOOK

Report

Delayed Nasdaq - 03/01 04:00:00 pm
11.95	USD		+0.93%

02/16

HOOKIPA PHARMA : to Participate in Upcoming SVB Leerink Global Healthcare Conference

2020

HOOKIPA PHARMA : Announces Closing of Public Offering of $80.9 Million of Common Stock and Preferred Stock, Including Full Exercise of Underwriters Option

2020

HOOKIPA PHARMA : Pockets Extra $6 Million After Underwriters Exercise Over-Allotment Options; Total Proceeds Climb Near $81 Million

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

02/23/2021	02/24/2021	02/25/2021	02/26/2021	03/01/2021	Date
11.48(c)	11.76(c)	11.65(c)	11.84(c)	11.95(c)	Last
117 438	99 825	84 730	142 625	176 711	Volume
-3.04%	+2.44%	-0.94%	+1.63%	+0.93%	Change

More quotes

Financials (USD)

Sales 2020	18,7 M - -
Net income 2020	-48,3 M - -
Net Debt 2020	- - -
P/E ratio 2020	-6,34x
Yield 2020	-

Sales 2021	16,2 M - -
Net income 2021	-66,8 M - -
Net Debt 2021	- - -
P/E ratio 2021	-4,94x
Yield 2021	-

Capitalization	399 M 399 M -
Capi. / Sales 2020	21,4x
Capi. / Sales 2021	24,6x
Nbr of Employees	95
Free-Float	72,4%

More Financials

Company

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is developing products to prevent and cure infectious diseases and cancer. The Company's infectious and oncology product candidates HB-101, HB-201 and HB-202. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation...

Sector

Pharmaceuticals

Calendar

03/25

Earnings Release

More about the company

Notations Surperformance© of HOOKIPA Pharma Inc.

Trading Rating :

Investor Rating :

More Ratings

All news about HOOKIPA PHARMA INC.

02/16	HOOKIPA PHARMA : to Participate in Upcoming SVB Leerink Global Healthcare Confe..	AQ
2020	HOOKIPA PHARMA : Announces Closing of Public Offering of $80.9 Million of Commo..	AQ
2020	HOOKIPA PHARMA : Pockets Extra $6 Million After Underwriters Exercise Over-Allo..	MT
2020	HOOKIPA Pharma Announces Closing of Public Offering of $80.9 Million of Commo..	GL
2020	HOOKIPA PHARMA INC. : Amendments to Articles of Inc. or Bylaws; Change in Fisca..	AQ
2020	HOOKIPA PHARMA INC. : Entry into a Material Definitive Agreement, Other Events,..	AQ
2020	HOOKIPA PHARMA : Prices $75 Million Public Offering	MT
2020	HOOKIPA Pharma Announces Pricing of Public Offering of Common Stock and Prefe..	GL
2020	HOOKIPA PHARMA : Plans Underwritten Offering of Shares, Convertible Preferred	MT
2020	HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Preferr..	GL
2020	HOOKIPA PHARMA : Releases Positive Interim Data From Study of Potential HPV+ Ca..	MT
2020	HOOKIPA PHARMA INC. : Regulation FD Disclosure, Other Events, Financial Stateme..	AQ
2020	HOOKIPA PHARMA : Interim Phase 1 Monotherapy Data of HB-201 for the Treatment o..	AQ
2020	HOOKIPA PHARMA : RBC Adjusts HOOKIPA Pharma's Price Target to $22 From $18, Mai..	MT
2020	HOOKIPA PHARMA : Reports Positive Phase 2 Interim Data for Positive Phase 2 Int..	MT

More news

News in other languages on HOOKIPA PHARMA INC.

- No features available -

More news

Analyst Recommendations on HOOKIPA PHARMA INC.

2020	HOOKIPA PHARMA : RBC Adjusts HOOKIPA Pharma's Price Target to $22 From $18, Mai..	MT
2020	HOOKIPA PHARMA : Truist Starts HOOKIPA Pharma at Buy With $21 Price Target	MT

More recommendations

Provided by Scoopnest.com

Chart HOOKIPA PHARMA INC.

Duration : Period :

HOOKIPA Pharma Inc. Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends HOOKIPA PHARMA INC.

	Short Term	Mid-Term	Long Term
Trends	Neutral	Neutral	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	BUY
Number of Analysts	6
Average target price	22,00 $
Last Close Price	11,95 $
Spread / Highest target	134%
Spread / Average Target	84,1%
Spread / Lowest Target	33,9%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Jörn Aldag	Chief Executive Officer & Director
Reinhard Kandera	Chief Financial Officer & Director
Jan G. J. van de Winkel	Chairman
Igor Matushansky	Chief Medical Officer & Global Head-Research
Roman Necina	Chief Technology Officer

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

HOOKIPA PHARMA INC.	7.75%	399



JOHNSON & JOHNSON	1.23%	418 801
ROCHE HOLDING AG	-2.83%	281 718
NOVARTIS AG	-4.73%	196 893
ABBVIE INC.	1.18%	191 439
PFIZER INC.	-9.02%	187 968

More Results